Inhibition of lens epithelial cells by Fas-specific antibody activating Fas-Fas ligand system

O Nishi1, K Nishi, K Wada

  • 1Nishi Eye Hospital, Osaka, Nakamichi, Higashinari-ku, Japan okihior@nishi-ganka.or.jp

Current Eye Research
|January 23, 2002
PubMed
Abstract

Insights

Human cataract cells express apoptosis factors. Fas-stimulating monoclonal antibody inhibited lens epithelial cell proliferation, suggesting potential for preventing cataract complications.

Area of Science:

  • Ophthalmology
  • Cell Biology
  • Molecular Biology

Background:

  • Cataracts are a leading cause of vision loss, often involving changes in lens epithelial cells (LEC).
  • Apoptosis, or programmed cell death, plays a role in cataract formation and progression.
  • Understanding the molecular mechanisms of apoptosis in LEC is crucial for developing therapeutic strategies.

Purpose of the Study:

  • To detect specific apoptosis factors (Fas, Fas ligand) and intracellular apoptosis modulators (caspase 1, Bcl-2, Bcl-xL, Bax) in human cataractous LEC.
  • To investigate the effect of Fas-stimulating monoclonal antibody on inhibiting LEC proliferation.

Main Methods:

  • Reverse-transcriptase polymerase chain reaction (RT-PCR) was employed to analyze mRNA expression of apoptosis-related genes in LEC.
  • Human cataractous LEC were isolated from surgical specimens.
  • Fas-stimulating monoclonal antibody was applied at varying concentrations to cultured LEC, followed by cell counting to assess proliferation inhibition.

Main Results:

  • mRNA for Fas, caspase 1, Bcl-2, Bcl-xL, and Bax was successfully detected in human cataractous LEC.
  • Fas ligand mRNA was not detected in the studied samples.
  • Fas-stimulating monoclonal antibody demonstrated significant inhibition of LEC proliferation across all tested concentrations.

Conclusions:

  • Human cataractous LEC express key apoptosis-related genes, including Fas and its modulators.
  • Fas-stimulating monoclonal antibody exhibits potential in inhibiting LEC proliferation.
  • This suggests a possible therapeutic role for Fas-stimulating monoclonal antibody in preventing posterior capsule opacification post-cataract surgery.